NCT06161974Phase 2Recruiting

Study of Olutasidenib and Temozolomide in HGG

Study sponsor: Rigel Pharmaceuticals

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2029-06Estimated
Enrollment · participants60Estimated
Source updated2026-09-01Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview